454 Life Sciences Corporation
454 Life Sciences Corporation, a pioneering entity in the biotechnology sector, is headquartered in the United States. Founded in 2000, the company has made significant strides in the field of next-generation sequencing (NGS), revolutionising genomic research and diagnostics. With a focus on providing advanced sequencing solutions, 454 Life Sciences offers unique products that enable researchers to conduct high-throughput DNA sequencing with unparalleled accuracy and speed. Their innovative technologies have positioned them as a leader in the genomics industry, catering to a diverse clientele that includes academic institutions, pharmaceutical companies, and clinical laboratories. Notable achievements include the development of the 454 Sequencing System, which has set benchmarks for efficiency in genomic analysis. As a key player in the NGS market, 454 Life Sciences continues to drive advancements in personalised medicine and genomic research, solidifying its reputation as a trusted partner in the life sciences community.
DitchCarbon Score
How does 454 Life Sciences Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
454 Life Sciences Corporation's score of 83 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
454 Life Sciences Corporation, headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Roche Holding AG, which influences its climate commitments and emissions reporting. As part of its corporate family relationship, 454 Life Sciences Corporation inherits emissions data and climate initiatives from Roche Holding AG. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which are aimed at reducing greenhouse gas emissions across their operations. While specific reduction targets for 454 Life Sciences Corporation are not detailed, the overarching goals set by Roche Holding AG reflect a commitment to sustainability and climate action. The company is actively engaged in initiatives to enhance its environmental performance, although no specific figures or targets have been disclosed at this time. In summary, while 454 Life Sciences Corporation does not present its own emissions data or reduction targets, it aligns with the climate strategies and commitments of its parent company, Roche Holding AG, to drive progress in reducing carbon emissions and addressing climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 249,350,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 114,452,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 6,402,719,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
454 Life Sciences Corporation is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
